Skip to main
MMED

MMED Stock Forecast & Price Target

MMED Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Minimed Group is expected to experience strong growth due to its track record of innovation, entry into the MDI segment, and upcoming new products. With a seasoned CEO and a large global customer base, the company has a conservative valuation. However, competition and regulatory risks should be taken into consideration when evaluating the stock.

Bears say

Minimed Group is a scaled medical technology company that offers solutions for the management of diabetes, including Automated Insulin Delivery Systems and Smart Multiple Daily Injection Systems. While adoption of diabetes technology is expected to grow quickly, the company faces competition and pressure to offer economically attractive solutions, limiting pricing power and compressing margins. Additionally, reimbursement and coverage structures vary by country, posing potential risks to the company's future success and revenue. With the recent spin-off from Medtronic and access to a $500 million credit facility, the company has a strong balance sheet, but its future success will depend on the successful adoption of its new products and managing costs effectively.

MMED has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiniMed Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiniMed Group Inc (MMED) Forecast

Analysts have given MMED a Buy based on their latest research and market trends.

According to 10 analysts, MMED has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiniMed Group Inc (MMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.